Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Beactica

Beactica
2006 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Grant LATEST DEAL TYPE
$294K LATEST DEAL AMOUNT
9 INVESTORS
Description

Developer of therapeutics intended to facilitate the treatment for glioblastoma and other cancers. The company's LSD1-protein based therapeutics regulates the expression of disease-associated proteins in order to change the chromatin configuration that governs regulation of DNA transcription and improve immune system's ability to fight cancer, enabling medical practitioners to treat patients with cancer with improved efficiency and lesser risks.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Virdings allé 2
  • 754 50 Uppsala
  • Sweden

+46 018-56 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Beactica’s full profile, request a free trial.

Beactica Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Grant 18-Jun-2019 $294K Completed Profitable
8. Later Stage VC 04-Jun-2019 Completed Profitable
7. Later Stage VC 28-Aug-2018 Completed Profitable
6. Grant 23-Mar-2018 000.00 Completed Profitable
5. Later Stage VC 15-Dec-2014 Completed Profitable
4. Accelerator/Incubator Completed Profitable
3. Grant 20-Nov-2014 00000 Completed Profitable
2. Grant 14-Sep-2007 $187K Completed Startup
1. Early Stage VC 22-Nov-2006 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Beactica Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rigontec Formerly VC-backed Munich, Germany 000.00 000000&0 000.00
0000000 0000000000 Venture Capital-Backed Indianapolis, IN 00 000.00 0000000000 0 000.00
0000000000 Venture Capital-Backed Abingdon, United Kingdom 000 00000 00000000000 00000
000000 00000000000 Failed Transaction (M&A) Cambridge, MA 000 00000 000000&0
00000 000000000000 Formerly VC-backed New York, NY 00 000.00 000000000000 000.00
To view this company’s complete list of competitors, request access »

Beactica Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
SWElife Accelerator/Incubator 000 0000 000000 0
M2Capital Management PE/Buyout Minority 000 0000 000000 0
Horizon 2020 Government 000 0000 000000 0
UNIONEN Venture Capital Minority 000 0000 000000 0
European Commission Government 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Beactica Executive Team (4)

Name Title Board
Seat
Contact
Info
Per Kallblad Ph.D Co-Founder & Chief Executive Officer
Jan-Olof Karlsson Chief Financial Officer
Ulf Bremberg Ph.D Chief Scientific Officer

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »

Beactica Board Members (9)

Name Representing Role Since Contact
Info
Erik Walldén Self Board Member 000 0000
Gisela Sitbon Ph.D Self Chairman 000 0000
Hakan Wickholm Self Board Member 000 0000
Helena Danielson Ph.D Beactica Co-Founder, Consultant & Board Member 000 0000
Uli Hacksell Ph.D Self Board Member 000 0000

4 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »